Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab in Children and Adolescents With Chronic Migraine
NCT03832998Phase 3Completed
- Sponsor
- Amgen
- Start
- Sep 2019
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of erenumab in chronic migraine (3 arms), sponsored by Amgen. Primary endpoint: Monthly Migraine Days at 12 weeks. Started Sep 2019; status: completed.
02
Drugs
erenumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT03832998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03832998.